Monashee Investment Management Cuts Biodesix Stake by 95%

Hedge fund reduces position in the molecular diagnostics company

Published on Mar. 3, 2026

Got story updates? Submit your updates here. ›

Monashee Investment Management LLC lowered its stake in Biodesix, Inc. (NASDAQ:BDSX) by 95% during the third quarter, according to a filing with the Securities and Exchange Commission. The fund now owns 99,996 shares of the company's stock, down from nearly 2 million shares previously.

Why it matters

Biodesix is a molecular diagnostics company that develops blood-based tests to guide clinical decision-making for lung diseases, including lung cancer. The significant reduction in Monashee's position could signal a shift in investor sentiment around the company's prospects.

The details

According to the filing, Monashee Investment Management sold 1,900,004 shares of Biodesix during the third quarter, reducing its position by 95%. The fund now owns 99,996 shares, or 1.26% of the company's outstanding stock, worth an estimated $755,000.

  • Monashee Investment Management filed the disclosure with the SEC on March 1, 2026.

The players

Monashee Investment Management LLC

A hedge fund that previously held a significant stake in Biodesix, Inc.

Biodesix, Inc.

A commercial-stage molecular diagnostics company that develops blood-based tests for lung diseases, including lung cancer.

Got photos? Submit your photos here. ›

The takeaway

The significant reduction in Monashee Investment Management's stake in Biodesix could signal a shift in investor sentiment around the company's prospects, despite some positive analyst commentary. Investors will likely be closely watching Biodesix's financial performance and market positioning in the coming quarters.